Citadel Advisors
TBPH icon

Citadel Advisors’s Theravance Biopharma TBPH Stock Holding History

Citadel Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$198K Buy
+12,200
New +$216K ﹤0.01% 11431
2025
Q2 		– Sell
-1,400
Closed -$12.5K – 15036
2025
Q1 		$12.5K Buy
1,400
+1,100
+367% +$10.2K ﹤0.01% 13444
2024
Q4 		$2.82K Sell
300
-900
-75% -$8.19K ﹤0.01% 14049
2024
Q3 		$9.67K Sell
1,200
-1,900
-61% -$16.5K ﹤0.01% 13243
2024
Q2 		$26.3K Buy
3,100
+800
+35% +$7.22K ﹤0.01% 12396
2024
Q1 		$20.6K Buy
2,300
+2,200
+2,200% +$20.4K ﹤0.01% 12997
2023
Q4 		$1.12K Buy
+100
New +$1.01K ﹤0.01% 13872
2023
Q3 		– Sell
-5,000
Closed -$51.8K – 15095
2023
Q2 		$51.8K Sell
5,000
-24,500
-83% -$271K ﹤0.01% 11758
2023
Q1 		$320K Sell
29,500
-3,700
-11% -$39.1K ﹤0.01% 9253
2022
Q4 		$373K Buy
+33,200
New +$349K ﹤0.01% 8859
2021
Q4 		– Sell
-21,400
Closed -$158K – 14740
2021
Q3 		$158K Buy
+21,400
New +$239K ﹤0.01% 12312
2019
Q3 		– Sell
-12,000
Closed -$196K – 9744
2019
Q2 		$196K Buy
+12,000
New +$243K ﹤0.01% 8205
2016
Q1 		– Sell
-100
Closed -$2K – 7918
2015
Q4 		$2K Buy
+100
New +$1.59K ﹤0.01% 8584
2015
Q3 		– Sell
-6,700
Closed -$87K – 9226
2015
Q2 		$87K Buy
6,700
+5,100
+319% +$79.1K ﹤0.01% 7223
2015
Q1 		$28K Sell
1,600
-1,800
-53% -$33K ﹤0.01% 7726
2014
Q4 		$51K Sell
3,400
-6,500
-66% -$113K ﹤0.01% 7182
2014
Q3 		$228K Buy
9,900
+6,900
+230% +$200K ﹤0.01% 5593
2014
Q2 		$96K Buy
+3,000
New +$90.3K ﹤0.01% 6260

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's TBPH Position: Q1 2026 in Review

Citadel Advisors reduced its Theravance Biopharma (TBPH) stake by 63% in Q1 2026, selling an estimated $2.65M and leaving 86,091 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #6880.

Citadel Advisors first reported a position in TBPH in Q2 2014 and has held it in 33 quarters since. The position peaked at $5.35M in Q2 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Citadel Advisors held 86,091 shares of Theravance Biopharma worth $1.4M as of Q1 2026.
  • Citadel Advisors sold 149,609 Theravance Biopharma shares in Q1 2026, an estimated $2.65M.
  • Theravance Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6880 holding.
  • Citadel Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 33 quarters since.
  • Citadel Advisors's Theravance Biopharma position peaked at $5.35M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.